Department of Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland.
Hepatology, Department of Biomedical Research, University of Bern, Switzerland.
Semin Liver Dis. 2021 Nov;41(4):448-460. doi: 10.1055/s-0041-1731705. Epub 2021 Jul 9.
The burden of obesity and metabolic syndrome has determined a sharp increase in bariatric surgery (BS) procedures, which lead to marked weight loss, improved metabolic syndrome, reduced cardiovascular risk, and even improvement in nonalcoholic steatohepatitis (NASH). Despite these promising results, BS in patients with chronic liver disease can rarely lead to worsening of liver function, progression to cirrhosis and its complications, and even liver transplantation. On the other hand, since obesity in patients with cirrhosis is a major cofactor for progression to a decompensated stage of the disease and a risk factor for hepatocellular carcinoma, BS has been used to achieve weight loss in this population. In this review, we critically analyze the existing data on outcomes of BS in patients with cirrhosis and the possible mechanisms leading to fibrosis progression and worsening liver function in patients undergoing BS. Finally, we propose a set of measures that could be taken to improve the multidisciplinary management of liver disease in patients undergoing BS, including early recognition of malnutrition and alcohol misuse.
肥胖和代谢综合征的负担决定了减重手术(BS)程序的急剧增加,这导致显著的体重减轻、改善代谢综合征、降低心血管风险,甚至改善非酒精性脂肪性肝炎(NASH)。尽管取得了这些有希望的结果,但慢性肝病患者的 BS 很少导致肝功能恶化、进展为肝硬化及其并发症,甚至肝移植。另一方面,由于肝硬化患者的肥胖是疾病失代偿阶段进展的主要促成因素,也是肝细胞癌的危险因素,因此 BS 已被用于减轻这部分人群的体重。在这篇综述中,我们批判性地分析了现有的关于肝硬化患者 BS 结果的数据,以及导致纤维化进展和接受 BS 的患者肝功能恶化的可能机制。最后,我们提出了一系列可以采取的措施来改善接受 BS 的患者的肝病多学科管理,包括早期识别营养不良和酒精滥用。